Novel Intermittent Dosing Burst Paradigm in Spinal Cord Stimulation.


Journal

Neuromodulation : journal of the International Neuromodulation Society
ISSN: 1525-1403
Titre abrégé: Neuromodulation
Pays: United States
ID NLM: 9804159

Informations de publication

Date de publication:
Apr 2021
Historique:
revised: 17 02 2020
received: 15 08 2019
accepted: 18 02 2020
pubmed: 24 3 2020
medline: 19 8 2021
entrez: 24 3 2020
Statut: ppublish

Résumé

Intermittent dosing (ID), in which periods of stimulation-on are alternated with periods of stimulation-off, is generally employed using 30 sec ON and 90 sec OFF intervals with burst spinal cord stimulation (SCS). The goal of this study was to evaluate the feasibility of using extended stimulation-off periods in patients with chronic intractable pain. This prospective, multicenter, feasibility trial evaluated the clinical efficacy of the following ID stimulation-off times: 90, 120, 150, and 360 sec with burst waveform parameters. After a successful trial (≥50% pain relief) using ID stimulation, subjects were titrated with OFF times beginning with 360 sec. Pain, quality of life, disability, and pain catastrophizing were evaluated at one, three, and six months after permanent implant. Fifty subjects completed an SCS trial using ID stimulation settings of 30 sec ON and 90 sec OFF, with 38 (76%) receiving ≥50% pain relief. Pain scores were significantly reduced from baseline at all time points (p < 0.001). Improvements in quality of life, disability, and pain catastrophizing were aligned with pain relief outcomes; 45.8% of the subjects that completed the six-month follow-up visit used an OFF period of 360 seconds. ID burst SCS effectively relieved pain for six months. The largest group of subjects used IDB settings of 30 sec ON and 360 sec OFF. These findings present intriguing implications for the optimal "dose" of electricity in SCS and may offer many advantages such as optimizing the therapeutic window, extending battery life, reducing recharge burden and, potentially, mitigating therapy habituation or tolerance.

Identifiants

pubmed: 32202044
doi: 10.1111/ner.13143
pmc: PMC8247280
pii: S1094-7159(21)00041-6
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

566-573

Subventions

Organisme : Abbott Laboratories

Informations de copyright

© 2020 The Authors. Neuromodulation: Technology at the Neural Interface published by Wiley Periodicals LLC on behalf of International Neuromodulation Society.

Références

Neuromodulation. 2014 Feb;17(2):152-9
pubmed: 24655043
Neuromodulation. 2019 Feb;22(2):190-193
pubmed: 30456795
Clin J Pain. 2010 Jul-Aug;26(6):463-9
pubmed: 20551721
Neuromodulation. 2016 Jun;19(4):373-84
pubmed: 27150431
Physiotherapy. 1980 Aug;66(8):271-3
pubmed: 6450426
Handb Clin Neurol. 2013;116:39-54
pubmed: 24112883
Neuromodulation. 2020 Jan;23(1):56-63
pubmed: 31039294
Neuromodulation. 2010 Jul;13(3):218-23
pubmed: 21992835
Pain Physician. 2017 Nov;20(7):E1073-E1080
pubmed: 29149152
Neuromodulation. 2017 Oct;20(7):642-649
pubmed: 28834092
World Neurosurg. 2013 Nov;80(5):642-649.e1
pubmed: 23321375
Neuromodulation. 2019 Feb;22(2):219-228
pubmed: 29707900
J Behav Med. 2000 Aug;23(4):351-65
pubmed: 10984864
J Pain Symptom Manage. 2006 Apr;31(4 Suppl):S13-9
pubmed: 16647590
Neuromodulation. 2018 Jan;21(1):106-113
pubmed: 28980364
Pain Med. 2019 Jun 1;20(Suppl 1):S47-S57
pubmed: 31152177
Neurosurgery. 2010 May;66(5):986-90
pubmed: 20404705
J Neurosurg. 1970 May;32(5):560-4
pubmed: 5438096
Neurosurgery. 2019 May 1;84(5):1011-1018
pubmed: 29788145
Cerebrum. 2012 May;2012:7
pubmed: 23447793
Clin J Pain. 2008 Mar-Apr;24(3):244-52
pubmed: 18287831
Neurosurgery. 2002 Jul;51(1):106-15; discussion 115-6
pubmed: 12182407
Expert Rev Med Devices. 2015 Mar;12(2):143-50
pubmed: 25483825
Neuromodulation. 2012 Jan-Feb;15(1):13-9; discussion 20
pubmed: 22151660
Pain Pract. 2014 Jul;14(6):489-505
pubmed: 23834386
Neuromodulation. 2018 Jan;21(1):56-66
pubmed: 28961366
Neurosurgery. 1977 Sep-Oct;1(2):215-8
pubmed: 308197
Neurosurgery. 2008 Oct;63(4):762-70; discussion 770
pubmed: 18981888
Neuromodulation. 2010 Jan;13(1):68-9
pubmed: 21992768

Auteurs

Timothy R Deer (TR)

The Spine and Nerve Center of the Virginias, Charleston, WV, USA.

Denis G Patterson (DG)

Nevada Advanced Pain Specialists, Reno, NV, USA.

Javid Baksh (J)

Premier Pain Solutions, Asheville, NC, USA.

Jason E Pope (JE)

Jason E. Pope, Santa Rosa, CA, USA.

Pankaj Mehta (P)

Pain Specialists of Austin, Austin, TX, USA.

Krishnan V Chakravarthy (KV)

University of California San Diego Health Sciences, San Diego Health Care, San Diego, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH